SCHEMBL3008014

SCHEMBL3008014

Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccccc4C)cs3)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.57
ALDH1A1 P00352 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD11B1 P28845 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 1/20 0.52
USP2 O75604 1/20 0.52
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
AR P10275 1/20 0.49
GBA1 P04062 5/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017308 0.91 L3MBTL1 (0.55) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3017725 0.91 SMN1; SMN2 (0.55) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3006385 0.91 ALDH1A1 (0.71) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3021301 0.91 SMN1; SMN2 (0.55) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3023448 0.89 HSD11B1 (0.59) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3012414 0.89 MAPT (0.60) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3014924 0.89 AR (0.64) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3008996 0.89 ALDH1A1 (0.53) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3012786 0.89 SMN1; SMN2 (0.53) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1
SCHEMBL3014790 0.88 ALDH1A1 (0.58) L3MBTL1ALDH1A1SMN1; SMN2HSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885ALDH1A1 3510/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.